Search





Search





Markets
/
Stocks
/
onco
/

Onconetix Inc

ONCO

Add to Watchlist

0.819USD

+0.032+4.08%

Close 07-31 16:00（ET）Quotes delayed by 15 min

225.51KMarket Cap

0.00P/E TTM

Onconetix Inc

0.819

+0.032+4.08%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+4.08%

5 Days

-0.33%

1 Month

-24.21%

6 Months

-88.47%

Year to Date

-89.51%

1 Year

-95.40%

Key Figures

0.770Open

0.820High

122.28KVolume

0.00P/E TTM

--P/E Dynamic

--Dividend TTM

44.38%Turnover Ratio

0.786Prev. Close

0.754Low

60.59KTurnover

LossP/E Static

0.02P/B

0.00%Div Yield TTM

-57.73%ROA

382.50052wk High

0.29Volume Ratio

-58.90MNet Profit

275.52KShares

1376.5865EPS TTM

2.78Beta

-127.45%ROE

0.91152wk Low

8.37%Amplitude

-7.71%Gross Margin

225.51KMarket Cap

-1.84Reward/Risk

9.62%Risk Rate

TradingKey Stock Score of Onconetix Inc

Currency: USD Updated: 2026-07-30

Key Insights

Onconetix Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 115 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Onconetix Inc's Score

Industry at a Glance

Industry Ranking

115 / 155

Overall Ranking

332 / 4280

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Onconetix Inc Highlights

StrengthsRisks

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1294.63% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 815.37K.

Overvalued

The company’s latest PE is 0.00, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 26.70K shares, increasing 7.56% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.94.